Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15141616 | 0.83 | CA1 (0.47) | ROCK1LIPGLPLGSK3AGSK3B | |
| SCHEMBL29182912 | 0.81 | ROCK1 (0.40) | ROCK1LIPGLPLGSK3AGSK3B | |
| SCHEMBL22967051 | 0.81 | ROCK1 (0.40) | ROCK1LIPGLPLGSK3AGSK3B | |
| SCHEMBL118986 | 0.76 | CA1 (0.51) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL411983 | 0.75 | KMT2A (0.42) | PDGFRBKDRCXCR2MAPK1 | |
| SCHEMBL3322268 | 0.75 | LPL (0.45) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL3711933 | 0.75 | ROCK1 (0.46) | ROCK1LIPGLPLHIF1ACA1 | |
| SCHEMBL11423631 | 0.75 | MEN1 (0.39) | — | |
| SCHEMBL24269985 | 0.74 | LIPG (0.38) | LIPGLPLGSK3AGSK3BHIF1A | |
| SCHEMBL1553789 | 0.74 | GSK3A (0.44) | LIPGLPLGSK3AGSK3BHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ROCK1 2340/4885LIPG 4309/4885LPL 4498/4885 |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ROCK1 2340/4885LIPG 4309/4885LPL 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.